A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-Center Study to Evaluate the Effect of JNJ-16269110 on Hepatic Triglyceride Content in Obese Subjects.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Usistapide (Primary)
- Indications Obesity
- Focus Pharmacodynamics; Pharmacogenomic
- 24 Jan 2013 Biomarkers information updated
- 07 Aug 2012 Janssen-Cilag added as trial association and lead trial centre as reported by European Clinical Trials Database.
- 07 Aug 2012 Additional trial locations (Netherlands, Sweden) added as reported by European Clinical Trials Database.